SV

Street Verdict

Analyst Scorecard

GLAXO · NSE

GlaxoSmithKline Pharmaceuticals Limited

₹2,727.6

+0.52% (+₹14.2)

Prev. close

₹2,713.4

Volume

84,480

Delivery %

59.9%

As of

20 Nov 2026

Price history

₹2,727.6-₹149.8 (-5.21%) · 3M
18 Aug 2026 → 20 Nov 2026
2,5002,6002,7002,8002,9003,0003,10018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 2 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix. It also provides respiratory specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease; and Seretide. In addition, the company offers general medicines, including Augmentin, an oral antibiotic for respiratory tract infections, surgical prophylaxis, dental infections, and skin infections; Ceftum, an anti-infective medicine; Calpol and Calpol T for pain management; Eltroxin for the treatment of hypothyroidism; Neosporin, Betnovate, T-bact, Physiogel, Tenovate, and Flutivate for dermatology indications; and CobadexCZS and CCM, which are mineral, vitamins, and nutrition products. Further, it provides oncology medicines, including Jemperli and Zejula. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is headquartered in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.

Details

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Mr. Bhushan Akshikar

Headquarters

Mumbai

Employees

3,103

Key stats

Market cap

₹42,995.25 Cr

P/E ratio (TTM)

37.5

Dividend yield

2.21%

EPS (TTM)

₹67.68

Beta (1Y · daily vs NIFTY 50)

0.50

Beta (5Y · monthly vs NIFTY 50)

0.58

Shares float

4.13 Cr

EPS · quarter ended Jun 2026

₹14.00

Financial Performance

01 · Financials

0 Cr1000 Cr2000 Cr3000 Cr4000 Cr₹0%20%40%60%FY21FY22FY23FY24FY25FY26
RevenueNet incomeNet income ÷ revenue

EBITDA is omitted from this chart: coverage begins inside the plotted window, and every plotted period must carry a complete point set — the P&L table below has the available figures.

02 · Earnings Per Share (EPS)

050100150₹FY21FY22FY23FY24FY26

03 · Dividend Profile

0255075100₹-100%0%100%200%17 Jul 2019 Jul 2107 Jul 2230 Jun 2331 May 2407 Nov 2430 May 2529 May 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-100%0%100%200%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr2000 Cr4000 Cr6000 Cr₹0×0.5×1×1.5×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr2000 Cr4000 Cr6000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

0 Cr500 Cr1000 Cr1500 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹3,198.86 Cr₹3,278.03 Cr₹3,251.72 Cr₹3,453.71 Cr₹3,726.03 Cr₹3,821.67 Cr
EBITDA
₹633.31 Cr—₹903.98 Cr₹887.67 Cr₹1,327.98 Cr₹1,475.18 Cr
₹358.15 Cr₹1,695.00 Cr₹610.69 Cr₹589.96 Cr₹927.58 Cr₹1,035.98 Cr
Diluted EPS
₹21.14₹100.04₹36.05₹34.83—₹61.15

Total expenses (as filed), Employee benefit expense, Other expenses, EBITDA, Other income, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

EBITDA for Mar 2021 could not be checked against the company's own annual report: this page shows ₹633.31 Cr while the annual report gives ₹805.91 Cr (27.3% apart). That disagreement leaves the whole cross-check inconclusive, so EBITDA for Mar 2020 (the annual report alone gives ₹736.26 Cr) and EBITDA for Mar 2022 (the annual report alone gives ₹837.66 Cr) are left blank here too, rather than shown from only one of the two sources.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹3,115.00 Cr₹4,633.00 Cr₹3,327.00 Cr₹3,557.00 Cr₹4,108.00 Cr₹4,324.00 Cr
₹34.63 Cr₹20.08 Cr₹15.54 Cr₹18.67 Cr₹9.95 Cr₹33.27 Cr
Stockholders' equity
₹1,478.00 Cr₹2,663.00 Cr₹1,741.00 Cr₹1,777.00 Cr₹1,951.00 Cr₹2,267.00 Cr

CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹578.00 Cr₹811.00 Cr₹484.00 Cr₹582.00 Cr₹1,290.00 Cr₹903.00 Cr
Investing cash flow
₹418.58 Cr₹-405.50 Cr₹807.85 Cr₹8.72 Cr₹-45.80 Cr₹396.98 Cr
₹-696.00 Cr₹-524.00 Cr₹-1,543.00 Cr₹-562.00 Cr₹-769.00 Cr₹-737.00 Cr
Capital expenditure
₹-44.00 Cr₹-35.00 Cr₹-44.00 Cr₹-31.00 Cr₹-23.00 Cr₹-55.00 Cr
End cash position
₹405.19 Cr₹286.19 Cr₹34.94 Cr₹64.17 Cr₹538.85 Cr₹1,102.05 Cr

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21–Jun 26(20Q)
Promoter75.00%
Public25.00%
Employee trusts0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
GlaxoSmithKline Pharmaceuticals Limited₹43,349.31 Cr₹2,531.440.619.1245.7%0.01+2.2%-3.3%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

GLAXO

GlaxoSmithKline Pharmaceuticals Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Simply Wall St · 16 days ago

GLAXO

GlaxoSmithKline Pharmaceuticals reports Q2 FY27 results and key appointments

InvestyWise · 19 days ago